NCT03720847View on ClinicalTrials.gov

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Suicidal Ideation
Interventions
DRUG

Estradiol Transdermal Patch 0.1 mg/24 hrs

Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation

DRUG

Oral Micronized Progesterone

100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation

DRUG

Inactive Clear Patch

Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation

DRUG

Placebo capsule

Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation

Trial Locations (1)

60657

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT03720847 - Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality | Biotech Hunter | Biotech Hunter